SB202190 (FHPI)

Catalog No.S1077

SB202190 (FHPI) Chemical Structure

Molecular Weight(MW): 331.34

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 46 Publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.
Targets
p38α [1]
(Cell-free assay)
p38β [1]
(Cell-free assay)
50 nM 100 nM
In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. [2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. [3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). [4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. [6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT-116 MmLWSpVv[3Srb36gRZN{[Xl? NGrSdZAzPSEQvF2= MVuzNEBucW5? NEi1N5hFVVORwrC= NVrQbJdD[XS2ZX71ZZRmeyC2aHWgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJI9nKGiERD2yJIlvKHKnc4DvcpNqfmVidH:gSGE> NEX4cZAzPjJ{M{K1NS=>
MDA-MB-231 NYXKNYxUTnWwY4Tpc44hSXO|YYm= MViyJO69VQ>? NV\uSXNvOjRiaB?= M{fafoxme3OnbnXzJGNEVDJiaX7keYN1cW:wIHL5JHRPTs7z NULKN2FLOjZzMEC4OFg>
rBMSCs NXWxUmRPTnWwY4Tpc44hSXO|YYm= NUjvR|ZPOTBizszN MUeyMlUhcA>? MUXk[ZBz\XO|ZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCHUlugZY5lKHB|OB?= NV;xcGJ5OjZyNUOyOlY>
MG63 NHvwXpJHfW6ldHnvckBCe3OjeR?= MXixNE8zOC9|MDFOwG0> NUS4[GZWOjRiaB?= M1G1[pNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBt\X[nbDDv[kBxcG:|cHjvdplt[XSnZDDwN|ghcW6mdXPl[EBjgSCFZFPsNkBqdiCjIHPvcoNmdnS{YYTpc44hNWSncHXu[IVvfCCvYX7u[ZI> M1XZ[lI2QTl6M{Gy
MG63 NGDrNFFCeG:ydH;zbZMhSXO|YYm= M3TzVlExNzJyL{OwJO69VQ>? NV:xdG9oOjRiaB?= MUDzbYdvcW[rY3HueIx6KGSnY4LlZZNm\CC2aHWgZZBweHSxc3nzJJJifGVib3[gUWc3OyCrbnT1Z4VlKGK7IFPkR4wz NU[2SZp6OjV7OUizNVI>
HTSMCs MnTrSpVv[3Srb36gRZN{[Xl? MoD2NE4yNzFxMUCg{txO NFPRTHcyKGh? M1rhcIlvcGmkaYTl[EBEV1KPLUKtbY5lfWOnZDDIU{0yKHC{b4TlbY4hdGW4ZXzzJIFv\CCvUl7BJIV5eHKnc4Ppc44> Mmm3NlU6OjF2NkS=
MIA PaCa-2 NET1NXVHfW6ldHnvckBCe3OjeR?= M1n2U|IxyqEQvF2= MWWyOEBp NFrFbItz\WS3Y3XkJIxi[3SjdHWgZYNkfW23bHH0bY9vKGmwIHPvcYJqdmG2aX;uJJdqfGhiYn;0bEAzNUSJIHHu[EBFNWGubH;z[eKh MkjmNlU5QDh2OEm=
MIA PaCa-2 Mn\sSpVv[3Srb36gRZN{[Xl? NHXtV2gzOMLizszN NFP3d5AzPCCq MVvy[ZN2dHS|IHnuJIEhdW:mZYP0JIlvcGmkaYTpc44hd2ZiSFnGMVHPuSCycn;0[YlvKGGlY4XteYxifGmxbh?= NIrZOWUzPTh6OES4PS=>
BxPC-3 M1rX[GZ2dmO2aX;uJGF{e2G7 MVmyNOKh|ryP M4XqRlI1KGh? MWny[ZN2dHS|IHnuJIEhdW:mZYP0JIlvcGmkaYTpc44hd2ZiSFnGMVHPuSCycn;0[YlvKGGlY4XteYxifGmxbh?= NWO2ZVlMOjV6OEi0PFk>
AsPC-1 M2PFZWZ2dmO2aX;uJGF{e2G7 NVXZblExOjEEoN88US=> M3H1cVI1KGh? MkftdoV{fWy2czDpckBiKG2xZHXzeEBqdmirYnn0bY9vKG:oIFjJSk0y|rFicILveIVqdiCjY3P1cZVt[XSrb36= M4jMWlI2QDh6NEi5
MIA PaCa-2 MU\GeY5kfGmxbjDBd5NigQ>? MnzFNlDDqM7:TR?= MnrzNlQhcA>? MoDk[Y5p[W6lZYOgZ4xm[X[jZ3Wgc4YhWEGUUDD3bIVvKGOxbXLpcoVlKHerdHig[4x2[2:|ZTDhcoFtd2e| MX6yOVg5QDR6OR?=
MIA PaCa-2 MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPUZXczOMLizszN NG\5VpMzKGh? M2PkRpNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>? M4nxe|I2QDh6NEi5
BxPC-3 MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnPcIpuOjEEoN88US=> MmTxNkBp MoHmd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm Mo\5NlU5QDh2OEm=
AsPC-1 NH[xcmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoqzNlDDqM7:TR?= M1LFdVIhcA>? NFrsSZF{\W6|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V? NHv3WYozPTh6OES4PS=>
HEY MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6yNOKh|ryP NFL0SZIzKGh? MYDz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U> NVr2SHZwOjV6OEi0PFk>
OVCAR-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW2NlDDqM7:TR?= MYGyJIg> MYXz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U> MYqyOVg5QDR6OR?=
SK-OV-3 NH[0fGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7CNlDDqM7:TR?= MoqyNkBp M1;QRpNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>? NF24R2kzPTh6OES4PS=>
MH7A  NFLmc4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWSyOEBp M2\5N5JmcW6ob4Lj[ZMhfGinIHnubIljcXSxcomg[YZn\WO2czDv[kBZSU5? M3nnd|I2QDZ{OU[2
MH7A  MVzBdI9xfG:|aYOgRZN{[Xl? M3jSdlI2KM7:TR?= NXLFNWVQOjRiaB?= MVjy[ZZmenOnczDj[YxtKGO7Y3zlJIFzemW|dDDpcoR2[2WmIHL5JHhCViCjbnSgZ4F2e2WmIHHwc5B1d3OrczDv[kBk\WyuczD2bYEh[WO2aY\heIlwdiCxZjDKUms> NWTndJVMOjV6NkK5OlY>
SCC25 M4n6bWZ2dmO2aX;uJGF{e2G7 M1jEe|IxKM7:TR?= NHr0boQzPCCq M4jOV4lv[3KnYYPld{BifXSxcHjh[5khdGW4ZXy= NGHVbZYzPTh|NESwNC=>
HaCaT  M3TMc2Z2dmO2aX;uJGF{e2G7 M{S1elUhyrWP NVTwcFFrOjRiaB?= NWjmW3RFcW6qaXLpeJMhUU[QLd8zMYlv\HWlZXSgR2NNOjJicILv[JVkfGmxbjDs[ZZmdHN? M2S3ZVI2QDN2M{Wz
HaCaT  MmDsSpVv[3Srb36gRZN{[Xl? MnG5OUDDvU1? M4m0RVI1KGh? MV3pcohq[mm2czDJSm4u|rFvaX7keYNm\CCFQ1yyNkBxem:mdXP0bY9vKGyndnXsdy=> M3fN[VI2QDN2M{Wz
HPAEpiCs  NWnZW|FCTnWwY4Tpc44hSXO|YYm= MVqxM|MwOTBizszN NFi1c5QyKGh? NEDDSIxz\WS3Y3XzJHMyWC2rbnT1Z4VlKEmFQV2tNUBxem:2ZXnuJIFv\CCvUl7BJIV5eHKnc4Ppc44h[W6mIIDyc41wfGW{IHHjeIl3cXS7 MUmyOVc{PDlyMB?=
HPAEpiCs MV7GeY5kfGmxbjDBd5NigQ>? NIj4b|UyNzNxMUCg{txO M3\YRlEhcA>? Mn;6bY5pcWKrdIOgV|FRNXO2aX31cIF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbjCgxsA> M{jlWVI2PzN2OUCw
HPAEpiCs MXfGeY5kfGmxbjDBd5NigQ>? MnzYNU8{NzFyIN88US=> MoWyNUBp NU\XOop4cW6qaXLpeJMhWzGSIITpcYUu\GWyZX7k[Y51dHlic4TpcZVt[XSnZDDjMWp2diCyaH;zdIhwenmuYYTpc44> MXSyOVc{PDlyMB?=
K562 NU\keXVZTnWwY4Tpc44hSXO|YYm= NFPrd2kyOMLizszN NVWweoQ6OcLiaB?= NGi0ZopFVVOR NHS1U3JqdmirYnn0d{ByfWmwYXPybY5mNWmwZIXj[YQheDN6IF3BVGsheGixc4Doc5J6dGG2aX;u NWTwW5VsOjV4OESwOFM>
PANC-1 Ml3CSpVv[3Srb36gRZN{[Xl? Ml[wNVAh|ryP MnXHNUBp MX\lcohidmOnczD0bIUh[XW2b4DoZYdq[yCnZn\lZ5TDqA>? NGXyPXMzPTZ|MkKyNi=>
BxPC-3 MlHKSpVv[3Srb36gRZN{[Xl? MVKxNEDPxE1? M2\lbFEhcA>? M{jmSIVvcGGwY3XzJJRp\SCjdYTvdIhi\2mlIHXm[oVkfMLi NGrqbmEzPTZ|MkKyNi=>
K562  NUDKOJhyTnWwY4Tpc44hSXO|YYm= MWOwMlI2NTFizszN MnXaNlQhcA>? Mn;jd5VxeHKnc4Pld{Bz\XO4ZYLheJJwdC2rbnT1Z4VlKEh{QWigdIhwe3Cqb4L5cIF1cW:w MVeyOVYyQTN7Mh?=
THP-1 NX3uN2p2TnWwY4Tpc44hSXO|YYm= M1XyU|UhyrWP M2T2SVIhcA>? NUPWVHlSe2mpbnnmbYNidnSueTDheJRmdnWjdHXzJJNm[3KndHnvckBw\iCLTD2x{tEhcW6mdXPl[EBjgSB{N1;IR4hwdCCybIXzJGZUVC1zwrC= M4XKVlI2PTl6Nk[x
WB NU\XSJNKTnWwY4Tpc44hSXO|YYm= NHLlZXYzOOLCid88UeKh NGXZR48{OOLCiX3pci=> MmfW[IVkemWjc3XzJJRp\SCOUGOtJI9zKEyWQT3pcoR2[2WmIFnMMVYh[W6mIGTOSk3PucLicILv[JVkfGmxbh?= MWKyOVU{ODZ6Mh?=
RAW 264.7 M1frNGZ2dmO2aX;uJGF{e2G7 NHniT5cyOMLizszN NH\OPWY{OOLCiX3pci=> NGGxc21qdmS3Y3XzJINp[XKjY4Tldol{fGmlII\hZ5VwdGG2aX;uJI9nKE:Fc9Mg MmXQNlU1PjF|OUm=
RAW 264.7 M2G3bmZ2dmO2aX;uJGF{e2G7 NUG4V4pEOTEEoN88US=> M3vYO|Mx6oDLbXnu MWLheJRmdnWjdHXzJJRp\SCnZn\lZ5R{KG:oIF;QS{BwdiCxc4Tlc4Nt[XO2IILleJJi[3Srb36= M2DnNVI2PDZzM{m5
HaCaT  M1[1[2Z2dmO2aX;uJGF{e2G7 NHvJRY41OMLizszN MoHjN{0zPCCq MU\EUXNQ MV\y[YR2[2W|IITo[UBi[2O3bYXsZZRqd25ib3[gXm8uOQ>? NHfnenEzPTR|NUS4OS=>
H9c2 MlG1SpVv[3Srb36gRZN{[Xl? MknvOVDDqM7:TdMg NWfFSVk2OTJiaB?= MorKdoVlfWOnczDMSGghemWuZXHz[UBidmRiTV3QJIxwe3N? M1\nVVI2OjR3OEG4
HSCs NFvHW2NCeG:ydH;zbZMhSXO|YYm= NHTTSIMzPSEQvF2= Ml;lNlTDqGh? NEnFSHh{cWewaX\pZ4FvfGy7IHH0eIVvfWG2ZYOgWGcucW6mdXPl[EBi[3SrdnH0[YQhUFOFczDhdI9xfG:|aYO= NYn1OphtOjR7NkG5OVA>
THP-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fJTFczKGh? Mn75SG1UVw>? NF21UFVKSzVyPUSuO:69VQ>? NInNeI0zPDhzNUC4Oy=>
MDDCs NFzON4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXvSGE4OiCq MVPEUXNQ M4Xad2lEPTB{LkhOwG0> Mn[zNlQ5OTVyOEe=
MDDCs MVrGeY5kfGmxbjDBd5NigQ>? MWewMVE2KM7:TR?= MVG0PEBp MWjEUXNQ NES2SZV{fXCycnXzd4V{KEmITj5OtUBidmRiSWCtNVAheHKxZIXjeIlwdsLi NELtd5ozPDhzNUC4Oy=>
MDDCs MVfGeY5kfGmxbjDBd5NigQ>? NYHFOHhEOC1zNTFOwG0> Mnu5OFghcA>? Mn3ZSG1UVw>? M2KxUYlvcGmkaYTzJG1KWC1zYTygUWlRNTGkIHHu[EBTSU6WRWOgdJJw\HWldHnvci=> M1:wblI1QDF3MEi3
MDDCs NYnxe2JKTnWwY4Tpc44hSXO|YYm= M3O4b|ExKM7:TR?= MkLwN{42KGh? M2XyZmROW09? NXfSboVj[myxY3vzJGVDV1ZiR2CsJIJ2fCCwb4SgWnNXKEdibXXkbYF1\WRiZX70dpkhcW62bzDoeY1idiCPRFTDdy=> MWSyOFgyPTB6Nx?=
macrophages MXXGeY5kfGmxbjDBd5NigQ>? NHW5XGUy6oDLzszN NVnoWWx4PC534pEJbC=> NFj1cpVkd22ybHX0[Yx6KGmwaHnibZR{KE2WLVnJTU1qdmS3Y3XkJIFkfGm4YYTpc44hd2ZiTl[t{tpD NVvhe3NXOjR6MEi2N|M>
PDL  Ml;hSpVv[3Srb36gRZN{[Xl? MViyNOKh|ryPwrC= NXTMfVI2OzBibXnu NV36cHJ3TE2VTx?= NYW1RZBEe2mpbnnmbYNidnSueTDpcohq[mm2czD0bIUhfGWwc3ns[UBnd3KlZT3t[YRq[XSnZDDCUXAuOiCneIDy[ZN{cW:w MYCyOFU3OTB6MR?=
AGS MWjGeY5kfGmxbjDBd5NigQ>? M4K3blUh|ryP MX:zNEBucW5? MXvzeZBxemW|c3XzxsAyNWmwZIXj[YQh[2G|cHHz[U05KGGwZDDjZZNx[XOnLUOgZYN1cX[jdHnvci=> NYXKUoM5OjR3NEe4O|g>
H520 Mof6SpVv[3Srb36gRZN{[Xl? NInyfJgyOMLiwsXN M1vPd|EhcA>? M3HCPWROW09? NV;BdmlM\GWlcnXhd4V{KHSqZTDw[Y1mfHKneHXkMYlv\HWlZXSgUXNJOiCvUl7BJIFv\CCycn;0[YlvKGyndnXsdy=> MXSyOFU{ODR5NR?=
H1703 MYfGeY5kfGmxbjDBd5NigQ>? NELCSYEyOMLiwsXN NHPrb|cyKGh? MULEUXNQ NEPySY9l\WO{ZXHz[ZMhfGinIIDlcYV1emW6ZXStbY5lfWOnZDDNV2gzKG2UTlGgZY5lKHC{b4TlbY4hdGW4ZXzz NWez[|R7OjR3M{C0O|U>
H520 M333OmZ2dmO2aX;uJGF{e2G7 MmG3NVDDqML3TR?= NIr1OHoyOiCq M2rVemROW09? NV\v[IdvcW6qaXLpeJMheGWvZYTy[Zhm\C2nbHnjbZRm\CCPU1iyJJBzd3SnaX6gd5Ri[mmuaYT5 NIrkUowzPDV|MES3OS=>
H1703 NIn0bndHfW6ldHnvckBCe3OjeR?= MYGxNOKhyrWP M4rmdlEzKGh? MWPEUXNQ NFH5VZdqdmirYnn0d{Bx\W2ndILlfIVlNWWuaXPpeIVlKE2VSEKgdJJwfGWrbjDzeIFjcWyrdIm= MV[yOFU{ODR5NR?=
H520 NFOzXXdHfW6ldHnvckBCe3OjeR?= NIrqb2MyOMLiwsXN NEH6XIg3KGh? NHTqSmNFVVOR NH;FRVd{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhdGW4ZXzzJI9nKHWkaYH1bZRqdi2lb37qeYdifGWmIF3TTFIhcW5icHXt[ZRz\XinZD30doVifGWmwrDj[YxtKGyrbnW= NX3KNGZ3OjR3M{C0O|U>
H1703 MYPGeY5kfGmxbjDBd5NigQ>? NWjBUGR7OTEEoNM1US=> MXG2JIg> NHrzbpJFVVOR M3HTUJNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBt\X[nbIOgc4YhfWKrcYXpeIlvNWOxbnr1[4F1\WRiTWPINkBqdiCyZX3leJJmgGWmLYTy[YF1\WUEoHPlcIwhdGmwZR?= MlL2NlQ2OzB2N{W=
MC3T3-E1 Mn33SpVv[3Srb36gRZN{[Xl? NVO0eIo2OC5|L{OvN|Ah|ryP NITLW5oyKGh? NFHId|lifHSnboXheIV{KFSQRj5OtU1qdmS3Y3XkJG1OWC17IHX4dJJme3Orb36gbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYNCpC=> M2rhW|I1PTB{Nkm2
MC3T3-E1 Ml3VSpVv[3Srb36gRZN{[Xl? M1v1TFMxKM7:TR?= MkCwNUBp NGqwfGJifHSnboXheIV{KFSQRj5OtU1{fGmvdXzheIVlKHB|ODDNRXBMKHCqb4PwbI9zgWyjdHnvci=> NITtXoIzPDVyMk[5Oi=>
HUVECs  M2XSO2Z2dmO2aX;uJGF{e2G7 M2PRRVExyqEEtV2= MV6xJIg> MoqzbY5pcWKrdIOgWG5HNc7zLXnu[JVk\WRiQ2jDUFEheHKxZIXjeIlwdg>? NF7XN2IzPDR6N{m2OC=>
AGS  NGPSeoNHfW6ldHnvckBCe3OjeR?= NUS3PVNbOTEEoNM1US=> NF\OWpg{OMLibXnu MmjBbY5pcWKrdIOgTWwuOc7{LXnu[JVk\WRiYXP0bZZifGmxbjDv[kBxOzh? Mn7YNlQ1Pzl4OEG=
MKN-45 MXPGeY5kfGmxbjDBd5NigQ>? NIq3TnYyOMLiwsXN NFL0dlU{OMLibXnu NEXw[4tqdmirYnn0d{BKVC1zzsKtbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKHB|OB?= NGPMc5YzPDR5OU[4NS=>
AGS  NVHx[5ZtTnWwY4Tpc44hSXO|YYm= M2S0UFExyqEEtV2= Mnv1N|DDqG2rbh?= NVvNVWF6[XS2ZX71ZZRmeyCLTD2x{tIucW6mdXPl[EBISSClZXzsJI1q\3KjdHnvckBidmRiaX72ZZNqd25? NF;UZZgzPDR5OU[4NS=>
MKN-45 M1;DWWZ2dmO2aX;uJGF{e2G7 NHHIV5IyOMLiwsXN NHnld4s{OMLibXnu M1T4VYF1fGWwdXH0[ZMhUUxvMd8yMYlv\HWlZXSgS2Eh[2WubDDtbYdz[XSrb36gZY5lKGmwdnHzbY9v M1TI[VI1PDd7Nkix
AGS  MXTGeY5kfGmxbjDBd5NigQ>? MkjSNVDDqML3TR?= NH3xN5g{OMLibXnu NYK0cZkze2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgTYwuOc7{LXnu[JVk\WRiTV3QNkBidmRiTV3QPUBuWk6DIHX4dJJme3Orb36= Mn\ZNlQ1Pzl4OEG=
MKN-45 NG\ud25HfW6ldHnvckBCe3OjeR?= NGG0c2EyOMLiwsXN Mn\VN|DDqG2rbh?= NGDMfIh{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDJcE0y|rJvaX7keYNm\CCPTWCyJIFv\CCPTWC5JI1TVkFiZYjwdoV{e2mxbh?= MVWyOFQ4QTZ6MR?=
DCs NXfVb|VCTnWwY4Tpc44hSXO|YYm= NX3vPJZVOjEEoN88US=> NGLWbo8yyqCq M4jxfIRm[3KnYYPld{BKVC1zMjDwdo9lfWO2aX;u MWmyOFQ{PDZ|Nh?=
HUVEC  NEHBOYFHfW6ldHnvckBCe3OjeR?= NVzG[3ZHOjBizsztxsA> MYe1JIg> M3[3Z2ROW09? MlvOdoVlfWOnczDjfZRwc2mwZTDlfJBz\XO|aX;uJIxmfmWuczDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?= NYq4NlM6OjRzOEmwOlI>
A 549 MUTGeY5kfGmxbjDBd5NigQ>? M1jGfFUxKM7:TR?= NIrrOFUyKGh? NGjlXmhl\WO{ZXHz[ZMhfGinIHzleoVtKG:oIFnMMVjDqA>? NEj4cGMzPDF5OU[4PC=>
H520  NYqxNnJRTnWwY4Tpc44hSXO|YYm= NVTKV5g{PS9zMDFOwG0> NUjsbndQOSCq NYrxWId7TE2VTx?= MVzk[YNz\WG|ZYOgUXNJOiCycn;0[YlvKGG|IIflcIwh[XNibWLORUBt\X[nbIOgbY4h\2WoaYTpcoljNWW6cH;z[YQh[2WubB?= MWmyOFE{QDlyMx?=
H1703  NULWb2VETnWwY4Tpc44hSXO|YYm= MmnUOU8yOCEQvF2= MXKxJIg> MYnEUXNQ NULGNW5N\GWlcnXhd4V{KE2VSEKgdJJwfGWrbjDhd{B4\WyuIHHzJI1TVkFibHX2[Yx{KGmwIHfl[ol1cW6rYj3lfJBwe2WmIHPlcIw> MoixNlQyOzh7MEO=
H520  M4jifGZ2dmO2aX;uJGF{e2G7 MWOxNOKhyrWP MYSxNkBp NUDKN2pPTE2VTx?= MWHk[YNz\WG|ZYOgUXNJOiCvUl7BJIFv\CCycn;0[YlvKHO2YXLpcIl1gSCrbjDn[YZqfGmwaXKteJJm[XSnZDDOV2NNSyClZXzsdy=> NVG1[pg1OjRzM{i5NFM>
H1703  MXjGeY5kfGmxbjDBd5NigQ>? M13kVlExyqEEtV2= Mn24NVIhcA>? MVPEUXNQ NWfpSI9u\GWlcnXhd4V{KE2VSEKgcXJPSSCjbnSgdJJwfGWrbjDzeIFjcWyrdImgbY4h\2WoaYTpcoljNXS{ZXH0[YQhVlOFTFOgZ4VtdHN? M3ywcVI1OTN6OUCz
MCF-7  MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnSNVDDqM7:TR?= NUi2V|I6OjUEoHi= M3GweIlvcGmkaYTzJJRp\SCFUkGwPE1qdmS3Y3XkJINmdGxiZHXheIg> NIH1SHozPDF{OEi1Ny=>
HPAEpiCs NHPNW|dHfW6ldHnvckBCe3OjeR?= M33aZlAvOS9zL{GwJO69VQ>? M2fmSFEhcA>? M1jtNYlvcGmkaYTzJHRPTi4QsT3pcoR2[2WmIHPQUGEzyqCycn;0[YlvKGGwZDDtVm5CKGW6cILld5Nqd25? MUKyOFA3QTF3OB?=
podocytes MYXGeY5kfGmxbjDBd5NigQ>? NXrYSpZSOTEEoN88US=> MV[xJIg> NVuweG5QcW6qaXLpeJMhXEeIzsKxMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCyM{jNRXBMKGGwZDDFdosyNzMEoB?= M1O2XVI1ODN4MkGy
MCF-7 M37ibmZ2dmO2aX;uJGF{e2G7 NYjLfWluOTEEoN88US=> M2rDbFEhcA>? NWrDVpVCTE2VTx?= MUDy[YR2[2W|IITo[UBYSS2rbnT1Z4VlKHCqb4PwbI9zgWyjdHXkJJA{QCCPQWDL MXmyOFAyQTB7MB?=
MCF-7 MkfUSpVv[3Srb36gRZN{[Xl? NIfQTHIyOMLizszN M1XqcFI1KGh? M4i1V2ROW09? Mn7obY5kemWjc3XzJJRp\SCZQT3pcoR2[2WmIHHwc5B1d3Orcx?= NUPlVpk6OjRyMUmwPVA>
HAPI NInDT4NHfW6ldHnvckBCe3OjeR?= NFT0U5EyOC9{MD:0NOKh|ryP MnTHNUBp MnzDbY5pcWKrdIOgWGNFTC2rbnT1Z4VlKHB|OD;KUmshVUGSSzDwbI9{eGixconsZZRqd25? NHy2NY8zOzl4OUGyNC=>
HAPI MlHySpVv[3Srb36gRZN{[Xl? MVGyNOKh|ryPwrC= M3TzUlEhcA>? MX3EUXNQ MX;heJRmdnWjdHXzJHRETERvaX7keYNm\CCjY4TpeoF1cW:wIH;mJIlPV1NiYX7kJJBzd2S3Y4Tpc44> M{D0OFI{QTZ7MUKw
HepG2 M4[xemZ2dmO2aX;uJGF{e2G7 MnjpN|UxKG6P NF3neVczPCCq M4\PXYlvcGmkaYTzJJRp\SCmZXf1[Yxqdi2rbnT1Z4VlKGGldHn2ZZRqd25ib3[gdFM5VUGSSx?= NGXKPZAzOzl|M{G5PC=>
AGS  NUHxOG1tTnWwY4Tpc44hSXO|YYm= MXWxNOKh|ryP MoXZN|AhdWmw M3rWTYlvcGmkaYTzJINie3Cjc3WtN{Bi[3SrdnH0bY9vKGGwZDDpcohq[mm2aX;uJI9nKEWUSx?= MoDYNlM5PTB7OUS=
HepG2 NGXjbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUGyO2hzOC13MDFOwG0> NF3XVo41QCCq NH3KeXZqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MUmyN|gxPzVyOB?=
BEL7404 M4fodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;0dGUxNTVyIN88US=> Ml;3OFghcA>? MXTpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M{LU[FI{QDB5NUC4
HL7702 MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHLbmQxNTVyIN88US=> NI\6OGc1QCCq NWHySWJEcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NEPKbmYzOzhyN{WwPC=>
HepG2 Mnf6SpVv[3Srb36gRZN{[Xl? MnXONE02OCEQvF2= M2DSZlI1KGh? NXrTTWd6cW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDwN|gh\G:5boP0doVidSCycn;0[YlveyCPQWDLRXBMOixiQWTGNkwhVVONMTDhcoQhUFOSMkegbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFjObpozOzhyN{WwPC=>
BEAS-2B MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkW0NVAh|ryP NHPJPJc{OCCvaX6= M4LPbpJmfmW{c3XzJJRp\SCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gSCrbnT1Z4VlKGK7IFjDTS=> MWWyN|c5PDB|NB?=
BEAS-2B MojmR5l1d3SxeHn0fUBCe3OjeR?= MVSxNEDPxE1? NXXzXGxIOzBibXnu NETE[WNqdmirYnn0[YQhfGinIHnuZ5Jm[XOnIHnuJGxFUCCjbnSgTWwuQCCneIDy[ZN{cW:w M2f3VFI{Pzh2MEO0
BEAS-2B MlTVSpVv[3Srb36gRZN{[Xl? M{\kRlExKM7:TR?= NIfrb2k{OCCvaX6= M4\BRoRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHPhd5Bie2VvMzygRoFlKGGwZDDmZZM> M4G3ZlI{Pzh2MEO0
H9c2  M4q2NGZ2dmO2aX;uJGF{e2G7 MnXLNE4xOS9yLkGvNUDPxE1? Mn3RNUBp M2\zWoF1fGWwdXH0[ZMhXE6ILd8xMYlv\HWlZXSgUW1RNTliZYjwdoV{e2mxbjygcXJPSSCuZY\lcJMtKGGwZDDwdo9ud3SncjDhZ5Rqfmm2eR?= NEPEU|EzOzd5NEK1Ni=>
H9c2  MoDCSpVv[3Srb36gRZN{[Xl? MYmxJO69VQ>? NY\qWI57OSCq MXPy[YR2[2W|IGTOSk3PuSCmaYLlZ5RtgSC|dHnteYxifGWmIICzPEBOSVCNIIDoc5NxcG:{eXzheIlwdg>? M1m4Z|I{Pzd2MkWy
U937 NH;3UJFHfW6ldHnvckBCe3OjeR?= NITv[|gyOMLizszNxsA> NGW0XXUyKGh? M4fIZYFjem:pYYTld{B1cGViY3Hm[oVqdmViZX\m[YN1KG:wIF3LVE0yKGGwZDDQVFJC[87zIH3SUmEhfHKjboPjdolxfGmxbnHsJIxmfmWucx?= NGe1VWwzOzdyN{O4Oy=>
U937 MnHwSpVv[3Srb36gRZN{[Xl? NVLacJlCOTEEoN88UeKh NY\o[FV3OSCq MnTWZYJzd2ejdHXzJINi\m[naX7lMYlv\HWlZXSgUWtRNTFiZH;3ck1z\We3bHH0bY9vKGGwZDDQVFJC[87zIIXwMZJm\3WuYYTpc44> NHjZNWIzOzdyN{O4Oy=>
U937 MknLSpVv[3Srb36gRZN{[Xl? NXvsNWE{OTEEoN88UeKh MVyxJIg> NV;5bo5Ce3WycILld5NmeyClLVr1ckBidmRiQ2LFRkBxcG:|cHjvdplt[XSrb36gbY4h[2GoZnXpcoUufHKnYYTl[EBk\Wyuc9Mg M3nWWVI{PzB5M{i3
A549 M3v3W2Z2dmO2aX;uJGF{e2G7 MkjmNE4{NzNxM{Cg{txO M3\U[FEhcA>? NIXvTHd{cWewaX\pZ4FvfGy7IHH0eIVvfWG2ZYOgRXRR|rOVLX3l[IlifGWmIFPPXE0zKHC{b4TlbY4h[W6mIH3SUmEh\XiycnXzd4lwdiCjbnSgdJJwdW:2ZYKgZYN1cX[rdIpCpC=> MlfCNlM3QDB4N{S=
A549 MX;GeY5kfGmxbjDBd5NigQ>? NX;FWIpoOTEEoN88UeKh MX:wMVMxKG2rbh?= M{O4XYlvcGmkaYTzJGFVWM7|UzDpcoR2[2WmIIC0Nk9xPDRiTVHQT{BidmRicEO4JG1CWEticHjvd5Bpd3K7bHH0bY9v NWnDb3k1OjN4OEC2O|Q>
A549 M4LyPGZ2dmO2aX;uJGF{e2G7 M4\jeVExyqEQvF5CpC=> NF35booyKGh? NFq2bmJqdmirYnn0d{BCXFEQs2OgbY5lfWOnZDDOSk3PwkJicE[1JJN2[nWwaYSgdIhwe3Cqb4L5cIF1cW:wIHHu[EBPTi4QulKgdJJwdW:2ZYKgZYN1cX[rdIm= MU[yN|Y5ODZ5NB?=
A549 NUe1U4VXTnWwY4Tpc44hSXO|YYm= M1rIVVExyqEQvF5CpC=> NFXue4gyKGh? MoHjdoVlfWOnczDBWHDPu1Nvc4TpcZVt[XSnZDDjVGxCOiCyaH;zdIhwenmuYYTpc47DqA>? M4DOSVI{PjhyNke0
A549 NVXEfVRFTnWwY4Tpc44hSXO|YYm= NXjLNWl5OTEEoN88UeKh NE[4RW4yKGh? M2\pbpJm\HWlZYOgRXRR|rOVLXXubIFv[2WmIHXufplu[XSrYzDhZ5Rqfmm2eTDv[kBkWEyDMtMg MlzLNlM3QDB4N{S=
PC12 M2PqR2Z2dmO2aX;uJGF{e2G7 MoD2NVAwOjBxNECg{txO NIPtO5UyyqCq NUDlO|BUcW6qaXLpeJMhUk6NIHHu[EBxOzh? Mo\yNlM2QDR|NUe=
HK-2 NVPBVphPSXCxcITvd4l{KEG|c3H5 NXz4bHlzOjEEoN88US=> NWfYXIN2OjRiaB?= NIThSpZqdmirYnn0d{BGWktiYX7kJJA{QE2DUFu= MXGyN|U1OzF3MR?=
H9c2 MV7GeY5kfGmxbjDBd5NigQ>? NVnQdIVZOcLizszN NWj4V4t1OSCq M{\Qc5Jm\HWlZYOgWG5HNc7zLXnu[JVk\WRiTV3QMVkhdVKQQTDs[ZZmdHNiYX7kJJBzd22xdHXyJIFkfGm4aYT5 MUCyN|M2OzZ7OR?=
H9c2 NX35c5BlTnWwY4Tpc44hSXO|YYm= NYjKXmk6OcLizszN MnLwNUBp MkTRdoVlfWOnczDUUmYu|rFvZX7oZY5k\WRiQWCtNUBxem:vb4TldkBi[3Srdnn0fS=> MXeyN|M2OzZ7OR?=
H1650  MoiwSpVv[3Srb36gRZN{[Xl? M1zGW|ExyqEQvF5CpC=> M2rDRVEhcA>? MkTwSG1UVw>? NYK1WGlV\GWlcnXhd4V{KGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdHNib3[gSXJESzFiaX6gdIFkdGm2YYjlcE1mgHCxc3XkxsBk\Wyucx?= NHPIOmMzOzJ{OE[5Oi=>
H1703 MWPGeY5kfGmxbjDBd5NigQ>? NGO0d2IyOMLizszNxsA> M1HZbFEhcA>? NXf0N41HTE2VTx?= NICwU5Vl\WO{ZXHz[ZMh[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVteyCxZjDFVmNEOSCrbjDwZYNtcXSjeHXsMYV5eG:|ZXVCpINmdGy| MlzsNlMzOjh4OU[=
H1650  NEPBZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL5NVDDqM7:TdMg M1PBclEhcA>? M1zUdGROW09? MU\lcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NHzsTpozOzJ{OE[5Oi=>
H1703 M4nOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3y2SFExyqEQvF5CpC=> NFHLUIcyKGh? NEXQfXVFVVOR MWXlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NIjhW|UzOzJ{OE[5Oi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
mTOR / p-S6K / S6K / p-S6 / p-AKT / p-MK2; 

PubMed: 26844273     


CRC cells were treated with 10 μM SB202190 for 2 h and analyzed for mTOR signaling and on-target inhibition of p38 by immunoblot. 

pJNK1 / pJNK2 / JNK1 / JNK2 ; 

PubMed: 18222647     


A549 cells were treated with DMSO control or with 10 µM of SB202190 for 0.5, 1, 2, 3, 4, or 6 hours, and pJNK and unphosphorylated JNK were detected as described. 

26844273 18222647
Immunofluorescence
p-p38 / MMP9; 

PubMed: 24479681     


Immunocytochemical staining and confocal microscopy confirmed that IL-1β increased activation of p38 (red), and MMP2 and MMP9 (green) expression in MKN-45 GA cells; these effects were blocked by p38 siRNA or the p38 inhibitor SB202190.

24479681
Growth inhibition assay
Cell viability ; 

PubMed: 26844273     


Top panel: CRC cells were treated with various concentrations of SB202190 for 48 h. Lower panel: CRC cells were treated with SB202190 at 10 μM for different times. Cell growth was measured by SRB assay (means ± s.d. in triplet, n = 3 in triplet).

26844273
In vivo Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. [5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. [8]

Protocol

Kinase Assay:

[1]

- Collapse

In vitro kinase assays:

The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-33P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-33P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research:

[2]

- Collapse
  • Cell lines: Jurkat, and HeLa
  • Concentrations: Dissolved in DMSO, final concentrations ~50 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining.


    (Only for Reference)
Animal Research:

[5]

- Collapse
  • Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 12.5 μg
  • Administration: Administered via i.d.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (199.19 mM)
Ethanol 12 mg/mL (36.21 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 331.34
Formula

C20H14N3OF

CAS No. 152121-30-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy SB202190 (FHPI) | SB202190 (FHPI) supplier | purchase SB202190 (FHPI) | SB202190 (FHPI) cost | SB202190 (FHPI) manufacturer | order SB202190 (FHPI) | SB202190 (FHPI) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID